Preclinical characterization of CLSP-1025, a first-in-class, mutation-specific T-cell engager targeting a neoantigen derived from a common p53 mutation [0.03%]
靶向常见p53突变衍生neo抗原的首创新药CLSP-1025(TCE)的临床前研究
Michael F Maloney,Justina X Caushi,Lenore A Cullen et al.
Michael F Maloney et al.
Purpose: Targeting intracellular oncogenic mutations with T-cell engagers has the potential to expand precision immunotherapy beyond surface antigens. Here, we describe the preclinical characterization of CLSP-1025, a mut...
First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma [0.03%]
[211At].meta-碘苯基氮杂二环庚烷治疗肾上腺嗜铬细胞瘤或副神经瘤的首次人体、开放性、单臂Ⅰ期临床研究
Shozo Okamoto,Kaori Nomura,Tohru Shiga et al.
Shozo Okamoto et al.
Purpose: The efficacy of current therapeutic options for pheochromocytomas and paragangliomas, such as 131I-meta-iodobenzylguanidine (131I-MIBG), is limited owing to low complete response rates and a requirement for prolo...
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial [0.03%]
塞雷昔单抗联合贝伐珠单抗和化疗治疗晚期结直肠腺癌二线疗法：II期DeFianCe试验
Zev A Wainberg,Keun-Wook Lee,Jong Gwang Kim et al.
Zev A Wainberg et al.
Purpose: DeFianCe was a randomized phase 2 study evaluating sirexatamab, a Dickkopf-related protein 1 (DKK1)-neutralizing antibody, plus chemotherapy and bevacizumab as second-line therapy for metastatic colorectal cancer...
Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study [0.03%]
基于陆地标志的ctDNA分子反应代表了肺癌免疫治疗结果的早期预测因素：临床验证研究
Noushin Niknafs,Lavanya Sivapalan,Archana Balan et al.
Noushin Niknafs et al.
Purpose: Circulating tumor DNA (ctDNA) analyses are informative as an early indicator of immunotherapy response in advanced non-small cell lung cancer (NSCLC); however, the clinical value of ctDNA molecular response requi...
Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial [0.03%]
他尼戈替尼治疗晚期实体瘤的多激酶抑制作用：一项国际多中心Ib/II期临床试验的结果
Sarina A Piha-Paul,Chih-Yi Liao,Farshid Dayyani et al.
Sarina A Piha-Paul et al.
Purpose: Tinengotinib, a multikinase inhibitor targeting Aurora kinases A/B, fibroblast growth factor receptors (FGFRs) 1-3, vascular endothelial growth factor receptor-2, and Janus kinases 1-2, was evaluated in this phas...
A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02 [0.03%]
rucaparib联合nivolumab作为晚期胆道癌维持治疗的II期多中心临床试验：BilT-02研究
Arathi Mohan,Kent A Griffith,Laura W Goff et al.
Arathi Mohan et al.
Purpose: This phase 2 trial investigated rucaparib (PARP inhibitor) in combination with nivolumab in patients with advanced BTC without progression after 4-6 months of first-line platinum-based chemotherapy. ...
Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial [0.03%]
抗原受体修饰的T细胞治疗复发/难治性CD30阳性淋巴瘤的长期随访结果：一项单臂、多中心的I-II期临床试验
Xiangmin Wang,Qing Zhang,Dongmei Yan et al.
Xiangmin Wang et al.
Purpose: This report presents long-term outcomes of third-generation anti-CD30 CAR T-cell therapy in relapsed/refractory (r/r) CD30+ lymphoma patients. Pa...
Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT) [0.03%]
利用机器学习识别多模态标志物，为接受度伐利尤单抗联合曲美木单抗和化疗治疗可获益的患者（TRIDENT研究）
Ferdinandos Skoulidis,Salma K Jabbour,Edward B Garon et al.
Ferdinandos Skoulidis et al.
Purpose: POSEIDON (NCT03164616) was a randomized, open-label, multicenter phase 3 trial comparing first-line durvalumab with or without tremelimumab in combination with chemotherapy versus chemotherapy alone in patients w...
A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer [0.03%]
用于治疗前列腺癌患者的分批给药及多次循环的靶向抗PSMA放射性发射体225Ac-J591 I期剂量递增/扩展研究
Scott T Tagawa,Charlene Thomas,Abdul Baseet Arham et al.
Scott T Tagawa et al.
Purpose: To test safety of two regimens at differing levels of radioactivity of PSMA-targeted alpha radionuclide 225Ac-J591. Patients and methods: ...
Network Integrated Platform for Clinical Trials Navigation from the New South Wales Early Phase Clinical Trials Alliance [0.03%]
新南威尔士早期临床试验联盟的临床试验导航集成平台
Jia Liu,Max Farrow,Sandra S Hsing et al.
Jia Liu et al.
Purpose: Access to early-phase clinical trials (EPCTs) is increasingly constrained by delays in genomic testing and lack of coordinated system-level navigation. The New South Wales Early Phase Clinical Trials Alliance (NE...